These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
25. Protein Aggregation Inhibitors as Disease-Modifying Therapies for Polyglutamine Diseases. Minakawa EN; Nagai Y Front Neurosci; 2021; 15():621996. PubMed ID: 33642983 [TBL] [Abstract][Full Text] [Related]
27. N-Terminal Fragments of Huntingtin Longer than Residue 170 form Visible Aggregates Independently to Polyglutamine Expansion. Chen MZ; Mok SA; Ormsby AR; Muchowski PJ; Hatters DM J Huntingtons Dis; 2017; 6(1):79-91. PubMed ID: 28339398 [TBL] [Abstract][Full Text] [Related]
28. PolyQ: a database describing the sequence and domain context of polyglutamine repeats in proteins. Robertson AL; Bate MA; Androulakis SG; Bottomley SP; Buckle AM Nucleic Acids Res; 2011 Jan; 39(Database issue):D272-6. PubMed ID: 21059684 [TBL] [Abstract][Full Text] [Related]
29. Mimicking proteasomal release of polyglutamine peptides initiates aggregation and toxicity. Raspe M; Gillis J; Krol H; Krom S; Bosch K; van Veen H; Reits E J Cell Sci; 2009 Sep; 122(Pt 18):3262-71. PubMed ID: 19690053 [TBL] [Abstract][Full Text] [Related]
30. The Protein Structure Context of PolyQ Regions. Totzeck F; Andrade-Navarro MA; Mier P PLoS One; 2017; 12(1):e0170801. PubMed ID: 28125688 [TBL] [Abstract][Full Text] [Related]
31. A yeast model for polyalanine-expansion aggregation and toxicity. Konopka CA; Locke MN; Gallagher PS; Pham N; Hart MP; Walker CJ; Gitler AD; Gardner RG Mol Biol Cell; 2011 Jun; 22(12):1971-84. PubMed ID: 21508314 [TBL] [Abstract][Full Text] [Related]
32. Study of the aggregation mechanism of polyglutamine peptides using replica exchange molecular dynamics simulations. Nakano M; Ebina K; Tanaka S J Mol Model; 2013 Apr; 19(4):1627-39. PubMed ID: 23288093 [TBL] [Abstract][Full Text] [Related]
33. Molecular chaperones as modulators of polyglutamine protein aggregation and toxicity. Sakahira H; Breuer P; Hayer-Hartl MK; Hartl FU Proc Natl Acad Sci U S A; 2002 Dec; 99 Suppl 4(Suppl 4):16412-8. PubMed ID: 12189209 [TBL] [Abstract][Full Text] [Related]
34. Increased aggregation of polyleucine compared with that of polyglutamine in dentatorubral-pallidoluysian atrophy protein. Suzuki Y; Jin C; Yazawa I Neurosci Lett; 2013 Sep; 552():156-61. PubMed ID: 23933208 [TBL] [Abstract][Full Text] [Related]
36. CAG Expansions Are Genetically Stable and Form Nontoxic Aggregates in Cells Lacking Endogenous Polyglutamine Proteins. Zurawel AA; Kabeche R; DiGregorio SE; Deng L; Menon KM; Opalko H; Duennwald ML; Moseley JB; Supattapone S mBio; 2016 Sep; 7(5):. PubMed ID: 27677791 [TBL] [Abstract][Full Text] [Related]
37. The N terminus of the small heat shock protein HSPB7 drives its polyQ aggregation-suppressing activity. Wu D; Vonk JJ; Salles F; Vonk D; Haslbeck M; Melki R; Bergink S; Kampinga HH J Biol Chem; 2019 Jun; 294(25):9985-9994. PubMed ID: 31097540 [TBL] [Abstract][Full Text] [Related]
38. Exploding the Repeat Length Paradigm while Exploring Amyloid Toxicity in Huntington's Disease. Wetzel R Acc Chem Res; 2020 Oct; 53(10):2347-2357. PubMed ID: 32975927 [TBL] [Abstract][Full Text] [Related]
39. Ataxin-1 fusion partners alter polyQ lethality and aggregation. Rich T; Varadaraj A PLoS One; 2007 Oct; 2(10):e1014. PubMed ID: 17925862 [TBL] [Abstract][Full Text] [Related]
40. Expansion of polyalanine tracts in the QA domain may play a critical role in the clavicular development of cleidocranial dysplasia. Wu LZ; Xu XY; Liu YF; Ge X; Wang XJ J Genet; 2015 Sep; 94(3):551-3. PubMed ID: 26440098 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]